u/laila_dumitru

Sent a vial to PeptideMeter because there was almost nothing on file for this compound. 99.6% against a claimed 99.0%, and I posted it because the log needs entries.

Agreed that the published criteria are the authority. They are searchable and most people never look.

How many separate lots has anyone here tested?

Correction: that is the registration decision, not the subsidy listing. They are made by different bodies.

The national shortage database is a primary source with expected resolution dates attached. It is public, searchable, and consistently more accurate than reporting about it.

Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.

the Medsafe position in New Zealand is its own thing entirely

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

nothing here is approved as a standalone product and research material is not for human use

Monotherapy arm or combination arm?

keep the script and the receipt for private health claims

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

Subsidy criteria and authority requirements are published. For eligibility questions those documents are authoritative and this board is not.

Registration by the therapeutic goods regulator establishes that a product may be supplied. Subsidy listing is a separate decision about public funding, with its own criteria and its own timetable.

Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.

Australia or New Zealand?

Is this about registration or about subsidy?

Read the published criteria for my indication rather than asking. Twenty minutes, and it answered everything I had been guessing at.

Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.